Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 14/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451994 | 0.87 | PTGER1 (0.42) | PTGER1HSD11B1 | |
| SCHEMBL6449875 | 0.82 | PTGER1 (0.45) | PTGER1CYP2C9HSD11B1CCR5ALDH1A1 | |
| SCHEMBL6450663 | 0.79 | HSP90AA1 (0.38) | HSD11B1 | |
| SCHEMBL30955958 | 0.72 | PTGER1 (0.54) | PTGER1CCR5SLC6A4ALDH1A1HTT | |
| SCHEMBL3726426 | 0.72 | PTGER1 (0.54) | PTGER1CCR5SLC6A4ALDH1A1HTT | |
| SCHEMBL17049367 | 0.70 | CCR5 (0.56) | PTGER1CYP2C9CCR5SLC6A4ALDH1A1 | |
| SCHEMBL26262216 | 0.69 | PTGER1 (0.47) | PTGER1CCR5SLC6A4ALDH1A1HTT | |
| SCHEMBL30835001 | 0.69 | CCR5 (0.55) | PTGER1CYP2C9CCR5SLC6A4ALDH1A1 | |
| SCHEMBL28286296 | 0.69 | CCR5 (0.55) | PTGER1CYP2C9CCR5SLC6A4ALDH1A1 | |
| SCHEMBL6451311 | 0.69 | SYK (0.40) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | PTGER1 3096/4885CYP2C9 144/4885HSD11B1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.